A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is framed by uncertainty in light of the country’s recent political transition. Nevertheless, the industry is robust and ready to adapt, already reacting to recent negative media attention relating to drug pricing and price increases. With an increasing amount of innovation stemming from small biotechnology companies and projects spun out from universities into start-ups, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange.